Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Nov 2024All 48 dated mentions so far are from Nov 2024.
Where it's discussed
-
X / Twitter47 posts
-
YouTube1 videos
AI synopsis
What people are saying
Several discussions reiterate specific figures from the study, noting that only 25.7% are using aspirin for cancer prevention despite its proven efficacy, which reinforces the urgency of addressing misconceptions about the medication's benefits. This is noted through phrases like 'strong evidence' and 'significantly decrease', reflecting a tone of advocacy and a call to action for increased awareness and usage of aspirin among those with Lynch syndrome.
Most discussions reflect a general understanding and acceptance of the study's findings, with many emphasizing the low uptake of aspirin among patients with Lynch syndrome.
The posts indicate strong interest in the subject, as users mention specific statistics and facts from the study.
While there is some depth in the discussions, many posts simply reflect information rather than providing in-depth personal commentary or analysis.
Participants perceive the study's findings as having significant implications for cancer prevention strategies, as it highlights a clear gap in the uptake of preventive measures.
Abstract in brief
- Individuals with Lynch syndrome have a high risk of colorectal cancer, and a study showed that taking aspirin can reduce this risk by 60% if adhered to for 2 years or more.
- A survey conducted from 2020 to 2022 revealed that only 34.8% of participants were regularly taking aspirin or NSAIDs for cancer prevention, with an even lower percentage (25.7%) specifically using it for Lynch syndrome prevention.
- The study found that perceptions of the risks and benefits of taking aspirin were more influential on whether individuals chose to use it for prevention than demographic factors or knowledge about the disease.*
Top posts
Most liked on X and BlueskyStrong evidence from CAPP2 study finds that for patients w/ Lynch Syndrome, 600 mg per day of aspirin can significantly decrease the risk of colorectal cancer by approx. 60%, yet only ~35% of these patients are taking it. https://t.co/StkEeNrngB #CGAIGC24 #crcsm #LynchSyndrome https://t.co/W182l4iFR2
Michael Hall presents his abstract, "Modeling uptake of aspirin (ASA) and NSAIDS in Lynch syndrome (LS) to elucidate barriers to chemoprevention of hereditary cancers," published simultaneously in @JCOPO_ASCO https://t.co/boJMg7bX39 https://t.co/1XM8zwPuAs
In @JCOPO_ASCO a study on Lynch syndrome finds that only 25.7% of individuals use aspirin or NSAIDs for #cancer #prevention, despite proven benefits. Perceptions of benefits & risks drive uptake more than clinical factors. #CancerPrevention @OncoAlert
A wonderful reflection on the uptake of Aspirin as Lynch syndrome chemoprevention remains low by Dr. @doctormikehall https://t.co/RBrdfQqWEM Full study results at: https://t.co/QlkevpXGFc
Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome https://t.co/y78iZU2482 via @lynchsyndromirl
All mentions
Aspirin Use in Lynch Syndrome: An Analysis of Chemoprevention Uptake
Dr. Michael J. Hall discusses the uptake of aspirin as a chemopreventive measure in patients with Lynch Syndrome. Despite its proven ability to reduce colorectal cancer risk by 60% with proper adherence, only 34.8% of…
RT @AlexMannucci: A wonderful reflection on the uptake of Aspirin as Lynch syndrome chemoprevention remains low by Dr. @doctormikehall h…
RT @AlexMannucci: A wonderful reflection on the uptake of Aspirin as Lynch syndrome chemoprevention remains low by Dr. @doctormikehall h…
RT @AlexMannucci: A wonderful reflection on the uptake of Aspirin as Lynch syndrome chemoprevention remains low by Dr. @doctormikehall h…
A wonderful reflection on the uptake of Aspirin as Lynch syndrome chemoprevention remains low by Dr. @doctormikehall https://t.co/RBrdfQqWEM Full study results at: https://t.co/QlkevpXGFc
RT @BenWestphalen: In @JCOPO_ASCO a study on Lynch syndrome finds that only 25.7% of individuals use aspirin or NSAIDs for #cancer #preven…
In @JCOPO_ASCO a study on Lynch syndrome finds that only 25.7% of individuals use aspirin or NSAIDs for #cancer #prevention, despite proven benefits. Perceptions of benefits & risks drive uptake more than clinical factors. #CancerPrevention @OncoAlert
RT @JCOPO_ASCO: Strong evidence from CAPP2 study finds that for patients w/ Lynch Syndrome, 600 mg per day of aspirin can significantly dec…
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Lynchsyndromirl: Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome https://t.co/y78iZU2482 via @lynchsyndromirl
RT @Lynchsyndromirl: Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome https://t.co/y78iZU2482 via @lynchsyndromirl
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Lynchsyndromirl: Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome https://t.co/y78iZU2482 via @lynchsyndromirl
Uptake of Aspirin Chemoprevention in Patients With Lynch Syndrome https://t.co/y78iZU2482 via @lynchsyndromirl
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @Erman_Akkus:
RT @JCOPO_ASCO: Strong evidence from CAPP2 study finds that for patients w/ Lynch Syndrome, 600 mg per day of aspirin can significantly dec…
RT @CGAIGC: Michael Hall presents his abstract, "Modeling uptake of aspirin (ASA) and NSAIDS in Lynch syndrome (LS) to elucidate barriers t…
RT @CGAIGC: Michael Hall presents his abstract, "Modeling uptake of aspirin (ASA) and NSAIDS in Lynch syndrome (LS) to elucidate barriers t…
Michael Hall presents his abstract, "Modeling uptake of aspirin (ASA) and NSAIDS in Lynch syndrome (LS) to elucidate barriers to chemoprevention of hereditary cancers," published simultaneously in @JCOPO_ASCO https://t.co/boJMg7bX39 https://t.co/1XM8zwPuAs
RT @JCOPO_ASCO: Strong evidence from CAPP2 study finds that for patients w/ Lynch Syndrome, 600 mg per day of aspirin can significantly dec…
RT @JCOPO_ASCO: Strong evidence from CAPP2 study finds that for patients w/ Lynch Syndrome, 600 mg per day of aspirin can significantly dec…
RT @JCOPO_ASCO: Strong evidence from CAPP2 study finds that for patients w/ Lynch Syndrome, 600 mg per day of aspirin can significantly dec…
Strong evidence from CAPP2 study finds that for patients w/ Lynch Syndrome, 600 mg per day of aspirin can significantly decrease the risk of colorectal cancer by approx. 60%, yet only ~35% of these patients are taking it. https://t.co/StkEeNrngB #CGAIGC24 #crcsm #LynchSyndrome https://t.co/W182l4iFR2